Michael N. Needle, MD, and Chief Medical Officer of AVEO Oncology goes over the TIVO-1 Trial results first released in 2014. On August 28, 2017 it was announces that Tivozanib (FOTIVDA®) has been approved in the EU for RCC patients.
TIVO-1 Trial Results Data Approves Tivozanib in EU for RCC
